We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
51
Illumina
ILMN
$27.9B
$35.6M 0.5%
98,736
-105,824
-52% -$34.1M
SGMO
52
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$34.5M 0.49%
3,850,000
– –
VYGR icon
53
Voyager Therapeutics
VYGR
$184M
$34.2M 0.48%
2,712,083
-12,000
-0.4% -$140K
ICPT
54
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$33.8M 0.48%
704,976
-4,000
-0.6% -$309K
HCA icon
55
HCA Healthcare
HCA
$82.2B
$33.3M 0.47%
343,166
+70,200
+26% +$7.3M
JAZZ icon
56
Jazz Pharmaceuticals
JAZZ
$15.3B
$32.1M 0.45%
291,136
-80,201
-22% -$8.87M
HOLX
57
DELISTED
Hologic
HOLX
$30.3M 0.43%
531,089
-36,690
-6% -$1.8M
GBIO
58
DELISTED
Generation Bio
GBIO
$30.2M 0.43%
+144,000
New +$32.1M
MOH icon
59
Molina Healthcare
MOH
$12B
$29.3M 0.41%
164,572
+36,366
+28% +$6.19M
TDOC icon
60
Teladoc Health
TDOC
$1.74B
$28.9M 0.41%
151,299
-49,936
-25% -$8.75M
PACB icon
61
Pacific Biosciences
PACB
$422M
$28.9M 0.41%
8,363,741
+984,950
+13% +$3.35M
TFX icon
62
Teleflex
TFX
$5.93B
$28.5M 0.4%
78,333
– –
ZBH icon
63
Zimmer Biomet
ZBH
$17.4B
$27.2M 0.38%
234,333
+126,356
+117% +$14.6M
ALGN icon
64
Align Technology
ALGN
$12.5B
$27.1M 0.38%
98,869
-104,207
-51% -$23.5M
WVE icon
65
Wave Life Sciences
WVE
$1.1B
$27.1M 0.38%
2,602,858
– –
QTTB icon
66
Q32 Bio
QTTB
$346M
$26.4M 0.37%
96,507
+6,945
+8% +$1.85M
HMSY
67
DELISTED
HMS Holdings Corp.
HMSY
$26.4M 0.37%
814,264
+239,087
+42% +$6.92M
HCM icon
68
HUTCHMED
HCM
$1.95B
$26.1M 0.37%
947,674
+95,680
+11% +$2.08M
TMO icon
69
Thermo Fisher Scientific
TMO
$196B
$25.2M 0.36%
69,491
+29,939
+76% +$10M
IDXX icon
70
Idexx Laboratories
IDXX
$44.5B
$24.3M 0.34%
73,607
+31,696
+76% +$9.18M
DVA icon
71
DaVita
DVA
$15B
$23.8M 0.34%
+300,200
New +$23.4M
ABMD
72
DELISTED
Abiomed Inc
ABMD
$23.4M 0.33%
96,699
-11,373
-11% -$2.28M
TNDM icon
73
Tandem Diabetes Care
TNDM
$1.24B
$22.9M 0.32%
231,839
+36,801
+19% +$2.94M
MASI
74
DELISTED
Masimo
MASI
$22.2M 0.31%
97,541
+5,296
+6% +$1.16M
KZR
75
DELISTED
Kezar Life Sciences
KZR
$22M 0.31%
424,194
+72,305
+21% +$3.65M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.